Regulatory approval of CPX-351 for secondary AML
Charles Craddock et al.
UK NCRI AML17 trial update: everolimus addition for consolidation
Update on CAR T-cell therapy at the City of Hope
IMiDs induce hematopoietic malignancies
Limitations of targeted therapy for AML